肺高血圧治療

鮎沢 衛

doi:10.4264/numa.72.260

Journal of Nihon University Medical Association

Online ISSN : 1884-0779
Print ISSN : 0029-0424
ISSN-L : 0029-0424

Special Articles:

Drugs for Pulmonary Arterial Hypertension

Mamoru Ayusawa

Author information

Keywords: pulmonary arterial hypertension, =prostacyclin (Prostaglandin I2; PGI2), endothelin receptor antagonist, =phosphodiesterase 5 Inhibitor

JOURNAL FREE ACCESS

2013 Volume 72 Issue 5 Pages 260-261

DOI https://doi.org/10.4264/numa.72.260

Details

Abstract

The rapid development of pharmacological treatment for pulmonary arterial hypertension is progressing because of the discovery of the mechanism of interaction between pulmonary vascular endothelial cells and smooth muscle cells. Three types of pulmonary specific vasodilators, prostaglandin I2, endothelin receptor antagonist, and phosphodiesterase type-5 inhibitor have been introduced and are markedly effective in the clinical stage.

Content from these authors

Favorites & Alerts

Corresponding author

Register with J-STAGE for free!